Clonal Anergy
Clonal anergy is a peripheral immunological tolerance mechanism in which self-reactive T or B lymphocytes become functionally unresponsive after engaging antigen without required costimulatory signals.
Clonal anergy is a key mechanism of peripheral immunological tolerance in which a T lymphocyte or B lymphocyte survives antigen encounter but enters a long-lived state of functional unresponsiveness, failing to proliferate or secrete effector cytokines upon subsequent encounters with the same antigen—even when presented later by fully activated antigen-presenting cells. First demonstrated experimentally in T cell clones by Marc Jenkins and Ronald Schwartz in the late 1980s, clonal anergy enforces the two-signal model of lymphocyte activation: Signal 1 (antigen receptor engagement) in the absence of Signal 2 (costimulation) turns a lymphocyte off rather than on.
Because tissue-restricted self-antigens are routinely presented by resting, non-inflamed dendritic cells and parenchymal cells that lack innate pattern-recognition stimulation, clonal anergy provides a crucial backstop against autoimmunity for self-reactive clones that escaped central deletion in the thymus or bone marrow.
Molecular Signaling in T Cell Anergy
Full activation of a naive CD4+ or CD8+ T cell requires Signal 1—T cell receptor (TCR) binding to peptide–MHC—paired with Signal 2, engagement of CD28 on the T cell by CD80 (B7-1) or CD86 (B7-2) on a mature dendritic cell:
- Unbalanced calcium–NFAT signaling: When a T cell receives Signal 1 alone (without CD28 costimulation), intracellular Ca2+ rises and activates calcineurin, which dephosphorylates NFAT (nuclear factor of activated T cells). However, without CD28-driven Ras/MAPK/PKCθ signaling, AP-1 (Fos/Jun) is not assembled.
- Anergy gene program: NFAT homodimers—acting without AP-1—bind promoters of anergy-associated E3 ubiquitin ligases (GRAIL, Itch, and Cbl-b) and transcriptional repressors (Egr2, Egr3, and Ikaros).
- TCR signaling blockade: These E3 ubiquitin ligases tag proximal TCR signaling kinases (PLC-γ1, PKC-θ, and Zap70) for degradation, severing downstream IL-2 transcription and cell-cycle progression. Engagement of the inhibitory receptor CTLA-4 (which outcompetes CD28 for B7 ligands) actively reinforces this anergic state.
| Lymphocyte Type | Primary Anergy Trigger | Key Intracellular Mediators | Outcome on Restimulation |
|---|---|---|---|
| CD4+ / CD8+ T Cell | TCR + peptide–MHC without CD28/B7 | Calcineurin → NFAT (no AP-1); Cbl-b, Itch, GRAIL | Fails to produce IL-2 or divide; survives temporarily |
| B Cell | Chronic soluble self-antigen without T cell help | Continuous low Ca2+ oscillations; SHP-1 / SHIP-1 | IgM downregulated (retains surface IgD); excluded from follicles |
B Cell Anergy and Clonal Redemption
In B lymphocytes, chronic binding of soluble, low-valency self-antigens in the bone marrow or periphery without CD4+ T helper signals induces B cell anergy. Anergic B cells markedly downregulate surface IgM (while retaining IgD), arrest prior to entering B cell follicles (being excluded at the T–B border), and display shortened lifespans of only a few days due to elevated pro-apoptotic Bim.
Remarkably, recent studies show that some anergic B cells can undergo clonal redemption inside germinal centers if recruited by a cross-reactive foreign pathogen antigen paired with T cell help: somatic hypermutation mutates the B cell receptor away from self-reactivity while preserving high affinity for the foreign microbe.
Therapeutic Exploitation in Transplantation and Oncology
Clinically, blocking Signal 2 with CTLA-4–Ig (abatacept / belatacept) deliberately induces T cell anergy to treat rheumatoid arthritis and prevent organ transplant rejection. Conversely, tumors exploit anergy by presenting tumor antigens on immature, non-costimulatory dendritic cells; checkpoint blockade and agonistic CD40/TLR adjuvants aim to reverse tumor-induced T cell anergy. Furthermore, oral tolerance protocols—such as controlled allergen immunotherapy for peanut or dust-mite allergy—rely in part on repeated low-dose mucosal antigen presentation in non-inflammatory gut-associated lymphoid tissue to induce anergic T cells and Foxp3+ regulatory T cells that suppress IgE-mediated hypersensitivity. Because rapamycin (sirolimus) inhibits mTOR-driven G1-to-S cell-cycle progression even when CD28 costimulation is intact, pharmacologic mTOR inhibition can also enforce functional T cell anergy in transplant recipients, whereas cyclosporine and tacrolimus block calcineurin–NFAT signaling and can paradoxically prevent anergy induction in vitro.
Frequently Asked Questions
What happens when a T cell receives Signal 1 without Signal 2? Without CD28 costimulation, TCR signaling activates NFAT without AP-1, switching on E3 ubiquitin ligases (such as Cbl-b and GRAIL) that dismantle TCR signaling and render the T cell anergic (unresponsive).
Can clonal anergy be reversed? In experimental settings, supplying high concentrations of exogenous IL-2 (which bypasses the TCR block via mTOR/JAK-STAT signaling) or blocking inhibitory receptors can partially restore proliferation in anergic T cells.
How does B cell anergy prevent autoantibody production? Anergic B cells internalize surface IgM, activate inhibitory phosphatases (SHP-1/SHIP-1), and are excluded from entering lymphoid follicles where they could otherwise receive T cell help to differentiate into plasma cells.
References
- Schwartz, R. H. (1997). T cell clonal anergy. Current Opinion in Immunology. https://doi.org/10.1016/s0952-7915(97)80081-780081-7)
- Schwartz, R. H. (1990). A Cell Culture Model for T Lymphocyte Clonal Anergy. Science. https://doi.org/10.1126/science.2113314
- Powell, J. D., et al. (1999). Inhibition of Cell Cycle Progression by Rapamycin Induces T Cell Clonal Anergy Even in the Presence of Costimulation. The Journal of Immunology. https://doi.org/10.4049/jimmunol.162.5.2775